Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 8/20 | 0.59 |
| ▸ | GLP1R | P43220 | 3/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013478 | 1.00 | PTH1R (0.59) | PTH1RGLP1RECE1MUS81PCSK9 | |
| SCHEMBL30093077 | 0.91 | PCSK9 (0.64) | PTH1RGLP1RECE1MUS81PCSK9 | |
| SCHEMBL30533150 | 0.90 | EDNRA (0.64) | PTH1RGLP1RECE1MUS81EDNRA | |
| SCHEMBL30094127 | 0.89 | IL23R (0.57) | PTH1RGLP1RECE1MUS81IL23R | |
| SCHEMBL31622725 | 0.89 | GLP1R (0.57) | PTH1RGLP1RECE1MUS81EDNRA | |
| SCHEMBL30130580 | 0.88 | EDNRA (0.59) | PTH1RGLP1RECE1MUS81PCSK9 | |
| SCHEMBL30130549 | 0.88 | EDNRA (0.59) | PTH1RGLP1RECE1MUS81PCSK9 | |
| SCHEMBL30320524 | 0.88 | GLP1R (0.58) | PTH1RGLP1RECE1MUS81PCSK9 | |
| SCHEMBL30093029 | 0.88 | EDNRA (0.57) | EDNRAKISS1R | |
| SCHEMBL30093090 | 0.88 | PCSK9 (0.61) | PTH1RGLP1RECE1MUS81PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | CASE WESTERN RESERVE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | FN1, IDUA, INHA | PTH1R 2633/4885GLP1R 1754/4885ECE1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.